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http://www.rbej.com/content/10/1/67RESEARCH Open AccessBalancing selected medication costs with total
number of daily injections: a preference analysis
of GnRH-agonist and antagonist protocols by IVF
patients
E Scott Sills1*, Gary S Collins2, Shala A Salem1, Christopher A Jones3, Alison C Peck1 and Rifaat D Salem1Abstract
Background: During in vitro fertilization (IVF), fertility patients are expected to self-administer many injections as
part of this treatment. While newer medications have been developed to substantially reduce the number of these
injections, such agents are typically much more expensive. Considering these differences in both cost and number
of injections, this study compared patient preferences between GnRH-agonist and GnRH-antagonist based
protocols in IVF.
Methods: Data were collected by voluntary, anonymous questionnaire at first consultation appointment. Patient
opinion concerning total number of s.c. injections as a function of non-reimbursed patient cost associated with
GnRH-agonist [A] and GnRH-antagonist [B] protocols in IVF was studied.
Results: Completed questionnaires (n= 71) revealed a mean +/− SD patient age of 34 +/− 4.1 yrs. Most (83.1%)
had no prior IVF experience; 2.8% reported another medical condition requiring self-administration of subcutaneous
medication(s). When out-of-pocket cost for [A] and [B] were identical, preference for [B] was registered by 50.7%
patients. The tendency to favor protocol [B] was weaker among patients with a health occupation. Estimated
patient costs for [A] and [B] were $259.82 +/− 11.75 and $654.55 +/− 106.34, respectively (p < 0.005). Measured
patient preference for [B] diminished as the cost difference increased.
Conclusions: This investigation found consistently higher non-reimbursed direct medication costs for
GnRH-antagonist IVF vs. GnRH-agonist IVF protocols. A conditional preference to minimize downregulation (using
GnRH-antagonist) was noted among some, but not all, IVF patient sub-groups. Compared to IVF patients with a
health occupation, the preference for GnRH-antagonist was weaker than for other patients. While reducing total
number of injections by using GnRH-antagonist is a desirable goal, it appears this advantage is not perceived
equally by all IVF patients and its utility is likely discounted heavily by patients when nonreimbursed medication
costs reach a critical level.
Keywords: GnRH-antagonist, IVF, Preference, Patient cost, Health economics* Correspondence: dr.sills@prc-ivf.com
1Reproductive Research Division, Pacific Reproductive Center, PRC—Orange
County, 10 Post, Irvine, CA 92618, USA
Full list of author information is available at the end of the article
© 2012 Sills et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Sills et al. Reproductive Biology and Endocrinology 2012, 10:67 Page 2 of 8
http://www.rbej.com/content/10/1/67Background
GnRH-antagonists can serve an important role in advanced
reproductive treatments, because this pharmacological ap-
proach enables the IVF sequence to be reduced from
4-5wks to <2wks, and lower overall gonadotropin con-
sumption [1]. The attenuated stimulation associated with
GnRH-antagonists also has been shown to minimize OHSS
risk [2-4]. A brief stimulation regime is less physically
stressful and psychologically demanding for IVF patients
[5], and GnRH-antagonists have emerged as an important
facilitator for this goal. But despite the praiseworthy arrival
of GnRH-antagonists in the modern IVF armamentarium,
it can also mean higher medication costs for those IVF
patients who are required to pay for it themselves. Because
medications are relatively costly and may account for more
than half of the overall IVF treatment expense [6], the ‘out-
of-pocket’ costs of particular agents have special relevance
for fertility patients. Indeed, the laudable goal of reducing
total gonadotropin amount to yield an overall lower total
IVF cost (as promised by GnRH-antagonists) can only be
realized when all other economic factors remain constant.
And while it seems intuitive that the avoidance of unneces-
sary injections would appeal to IVF patients, it has never
been established if this preference is conserved even when
extra ‘out-of-pocket’ costs are encountered. Is the desire to
reduce the number of subcutaneous injections in IVF suffi-
ciently strong that the financial cost associated with GnRH-
antagonists is irrelevant? To explore this issue, our study
sought to characterize IVF patient opinion on the matter of
non-reimbursed medication costs associated with either a
GnRH-agonist or GnRH-antagonist protocols.Methods
Patients attending for reproductive endocrinology consult-
ation at an urban IVF referral center based in southern
California were invited to participate in this voluntary, an-
onymous questionnaire study. While this research was sub-
mitted for institutional review board (IRB) approval, it was
exempted because data were gathered by voluntary ques-
tionnaire where patient identifiers were not recorded and it
did not disrupt or manipulate life events. The study ques-
tionnaire was developed in a process similar to that
described by Saini et al. [7], with input from infertility
nurses, researchers, pharmaceutical executives, physicians
and public members.
Patients planning a standard (non-frozen) in vitro
fertilization (IVF) sequence with non-donor oocytes were
eligible for study entry. Patients with insurance coverage for
diagnostic tests & procedures, or those with any health in-
surance pharmacy benefit coverage for assisted fertility med-
ications, were excluded from analysis. Any patient planning
to acquire their fertility medications outside the United
States were also excluded.Study patients were informed that while multiple IVF pro-
tocols exist, no treatment approach has been consistently
proven superior to any other, and specific protocols were not
discussed in detail during the initial consultation. An outline
of a typical IVF sequence was presented, and the need for
self-administered injections was also discussed. They were
advised that their subsequent ovulation induction regime
and treatment timetable would be developed later, depending
on findings from pending diagnostic tests. Each patient was
counselled that her opinions were for research purposes
only, and that the actual treatment protocol may or may not
align with any preference expressed during the study. A
study questionnaire was given to patients at the end of the
appointment session to capture basic demographic and clin-
ical information including patient age and duration of infer-
tility, highest completed level of education, and history of
having initiated a previous IVF cycle which included inject-
able gonadotropins. Relevant medical background was also
queried, including history of self-administration of any other
injectable medication such as insulin for diabetes, immuno-
logical agents for rheumatoid arthritis, allergy shots for aller-
gies, etc. Because it was important to explore possible
occupational familiarity with injection equipment which
might bias patient opinion on self-injection, patients were
asked about their work history in healthcare settings. Next,
two mutually exclusive IVF treatment scenarios were con-
trasted. These two IVF variations ([A]=GnRH agonist begin-
ning with oral contraceptive pill overlap in the luteal phase
of the cycle immediately preceding ovarian stimulation, and
[B]=GnRH antagonist commencing after ovarian stimula-
tion) were characterized as having equivalent reproductive
outcomes but different in total number of injections [8].
For the purposes of this investigation, patients were
advised to make their responses with the assumption that
the only difference between [A] and [B] was the total num-
ber of daily s.c. injections (estimated at 19 vs. 9 days, re-
spectively). At our center, gonadotropins are not combined
with either GnRH-agonist or antagonist, in accordance with
manufacturer’s guidelines. The questionnaire concluded by
asking about the relative importance of reducing number of
injections as a function of additional cost that might be
associated with such a reduction. The questionnaire was
administered once during the initial consultation to each
patient during a two month study interval. In cases where
an IVF patient was accompanied by a partner, the two indi-
viduals were allowed to complete the form together if they
wished. There was no time limit established to complete
the questionnaire, which was filled out in a neutral, private
setting at the clinic (i.e., not under staff observation). No
penalty applied to patients who declined to participate, and
those who did participate received nothing of value. Com-
pleted questionnaires were collected at patient exit and
batched by front office staff for tabulation at the end of the
study interval.
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developed as follows: Preliminary “out-of-pocket” expense
audits were given from randomly sampled non-donor IVF
patients without insurance coverage (n=49) over the six-
month period immediately before study initiation. This
sub-group also contributed feedback during questionnaire
design, although no data collected in validation were
included in the final analysis. Because receipts were not al-
ways available to document precise costs borne by patients,
pharmacy records were used to verify exact the cost-to-
patient associated with option [A] and [B]. Retail pharma-
cies (n=11) serving Orange County, California (USA) were
contacted to provide a “cash price” for the two prescrip-
tions without rebates, coupons, incentives, or other special
offers associated with patient purchase of either:
[A]
Leuprolide acetate injection, sterile solution supplied in a
2.8 mL (multiple dose) vial, packaged as a 14-day kit
(NDC 0185-7400-85).
-or-
[B]
Ganirelix Acetate injection, prefilled (single dose) syringe
250 μg/0.5 mL of ganirelix acetate 0.1 mg (NDC 0052-
0301-51).
For this investigation, it was necessary to correct unit
price data for [B] by a uniform multiplier (x5) in accord-
ance with manufacturer’s recommendation for five days’
use per each IVF cycle. Since only one 14d kit of [A] would
be consumed per completed IVF cycle, a similar correction
was not required. Pharmacy prices (without sales tax) for
[A] and [B] were then individually tabulated and averaged
to supply the “out-of-pocket” patient cost for each. Patient
cost at pharmacy was calculated in 2012 U.S. dollars, with-
out rebates, special offers, discounts or other temporary
price adjustments for both protocols.
Statistical analysis
Analysis of variance was used to assess whether there was a
difference in patient age, educational level and treatment
preference. Chi-square (and Fischer’s exact) test were used
to evaluate the association between previous healthcare oc-
cupation and treatment preference. Cost data provided by
pharmacies were compared by Student’s t-test. Differences
where p<0.05 were considered significant.
Results
Completed questionnaires were returned by all 71 new
patients eligible for entry; aggregate data provided by all
patients are presented in Table 1. Distribution of IVF pa-
tient preference as a function of age is summarized in Fig-
ure 1. Mean +/− SD patient age was 34 +/− 4.1 yrs
(range= 24-42 yrs), and questionnaire responses stratifiedby patient age are presented in Table 2. A 4-year college
degree was the highest educational attainment for 33.8%
of study patients; responses according to education level
are summarized in Additional file 1: Table S1. Infertility
duration in our sample was 2.4 +/− 1.4 (range= 0.5-8 yrs),
although the mean “time trying to conceive” was not sig-
nificantly different among patients who preferred the
investigated treatment options (see Additional file 2: Table
S2). A current healthcare occupation, or history of having
ever worked in the health sector, was reported by 11
patients (15.5%), and these data are presented in Add-
itional file 3: Table S3. In this sample, 16.9% of patients
had undergone at least one prior IVF treatment at time of
study entry (either at this center or elsewhere), and an
analysis of questionnaire responses based on previous IVF
is given in Additional file 4: Table S4. Two patients (2.8%)
indicated that they currently were taking, or had ever
used, any medication requiring self-injection, but
responses from this subgroup were too limited to perform
a separate analysis.
For all pharmacies sampled, patient cost for [A] was con-
sistently lower that for [B], although the difference was not
uniform. Static cost analysis between [A] and [B] showed
that patients receiving protocol [A] would spend an average
of 60.3% less for this treatment component than if they were
assigned [B] during IVF. Actual mean +/− SD patient costs
for [A] and [B] as determined from retail pharmacy data
were $259.82 +/− 111.75 and $654.55 +/1 106.34, respect-
ively (p<0.001). Data spread for non-reimbursed pharmacy
costs associated with [A] and [B] are depicted in Figure 2.
Discussion
At least two pharmacologic approaches have been devel-
oped to prevent a premature LH surge during controlled
ovarian stimulation in assisted reproduction. One technique
is the long protocol of gonadotrophin-releasing hormone
agonist (GnRH-a), which involves initiation of GnRH-a ei-
ther in the mid-luteal or early-follicular phase of the cycle
prior to ovarian stimulation. Follicular recruitment via
gonadotropins is delayed until pituitary desensitization has
been achieved, usually requiring 2-3wks [9]. A more recent
method utilizes gonadotrophin-releasing hormone antago-
nists (GnRH-antagonists), which can achieve complete pi-
tuitary suppression within 4-6 h of administration [10].
Accordingly, administration of GnRH-antagonists can fol-
low gonadotrophin administration bringing a dramatic re-
duction in duration of the IVF treatment cycle [11]. This
substantially lowers the number of injections required dur-
ing IVF, and may improve drug compliance and/or prevent
errors during drug administration [12]. The use of GnRH-a
and GnRH-antagonists in assisted fertility treatments has been
the focus of considerable comparative research [1,13-16].
Reproductive outcomes, as well as safety and efficacy,
between these two treatment approaches are thought to be
Table 1 Aggregate responses from IVF patients (n=71) concerning treatment preferences as a function of various cost
breakpoints
Question n (%)
In your opinion, which factor is the most important regarding your upcoming fertility treatment?
“Reducing the total number of injections is most important to me” 8 (11.3)
“Reducing out-of-pocket cost is most important to me” 17 (23.9)
“If A and B work equally well (i.e., same pregnancy rate) then I wouldn’t care” 18 (25.4)
”I would prefer B, but out-of-pocket cost would influence my choice” 28 (39.4)
Assuming there was no difference in your out-of-pocket cost for A and B, what would you prefer?
“I would definitely prefer treatment A” 3 (4.2)
“If both work equally well (i.e., same pregnancy rate) then I wouldn’t care” 29 (40.8)
“I would definitely prefer treatment B” 36 (50.7)
“I don’t know” 3 (4.2)
If reducing the total number of injections is important to you (Treatment B), and you would be willing to pay some extra for this,
how much more would you be willing to pay?
“I would pay up to $100 more for treatment B” 50 (70.4)
“I would pay $100-500 more for treatment B” 18 (25.4)
“I would pay more than $500 for treatment B” 2 (2.8)
“The cost difference wouldn’t matter, because I would still want Treatment B anyway” 1 (1.4)
Next, assume there is a difference in your ‘out-of-pocket’ cost for these two treatments. Treatment A will cost you about $260,
while Treatment B will cost you about $650.What would you do based on this information?
“I would prefer Treatment A based on this difference” 55 (77.5)
“If both work equally well (i.e., same pregnancy rate) then I wouldn’t care” 7 (9.9)
“I would prefer Treatment B based on this difference” 9 (12.7)
“I don’t know” 0
Note: Treatment A=GnRH-agonist, Treatment B =GnRH-antagonist.
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side GnRH-a as mainstream therapeutic agents used widely
at infertility units worldwide.
Interestingly, direct comparisons of traditional GnRH-a
and newer GnRH-antagonist IVF protocols have rarely
included pricing [21], and none have specifically evaluated
patient opinion concerning the non-reimbursed cost for
these medications. One multi-center study reported that
the medicines needed for IVF account for more than half of
the total treatment cost [6]. In California (and throughout
the United States), GnRH-antagonists are protected by pa-
tent and command a significantly higher price compared to
older GnRH-a preparations which are now available as gen-
eric substitutes. Particularly for patients whose first priority
is to lower the absolute cost of IVF, if the two approaches
have the same efficacy, the additional expense of a newer
medication must be carefully scrutinized.
Economics is the study of scarcity, where a choice in one
direction necessarily comes at the expense of what might
otherwise be available in another direction. Once an IVF
patient has made her choice to begin treatment, many will
have already made the decision to forego services or goods
that they could otherwise have afforded prior to starting
IVF. Although IVF patients do, in general, prefer fewerinjections, our investigation reveals that patients can some-
times make a trade-off in favor of lower out-of-pocket costs
but in ways which run counter to this “fewest possible
shots” axiom. This research is believed to be the first to ex-
plore this equilibrium, and while larger studies are needed,
several noteworthy observations warrant discussion. First,
our data align with previous studies where IVF patients
responded positively to the concept of simplified IVF treat-
ment enabled by a GnRH-antagonist [12,22-24]. Just over
half of our study patients (50.7%) indicated a definite pre-
ference for GnRH-antagonist, if their ‘out-of-pocket’ cost
difference between this and GnRH-a was zero. The value of
this preference among IVF patients still needs refinement,
but we were able to show that if the cost gap is relatively
small (e.g., up to $100) as compared to total treatment cost,
most patients (70.4%) will pay the extra expense to obtain
the GnRH-antagonist associated with fewer injections.
However, this study shows that when the ‘out-of-pocket’
cost difference increases, patient preference reverts to the
less expensive GnRH-a product in most (77.5%) cases. Our
data suggest that although most IVF patients associate
greater comfort with GnRH-antagonists [25], this effect is
not unlimited and will be lost when the GnRH-antagonist
is perceived as too expensive.
Figure 1 Patient preference to reduce number of daily injections vs. IVF patient age. Preference distribution regarding decreasing the
number of daily injections and importance of reducing out-of-pocket (non-reimbursed) cost as a function of IVF patient age, where patients
recorded their priority for A (prefer to reduce total number of daily injections), B (prefer to reduce out-of-pocket cost), C (no preference if there
were no difference in cost), or D (prefer GnRH-antagonist, but this would be influenced by cost).
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ence of age on treatment preference if there were no differ-
ences in treatment costs, such that younger IVF patientsTable 2 Responses from IVF patients (n=71) stratified by age
as a function of various cost breakpoints
Question
In your opinion, which factor is the most important regarding your upcomi
“Reducing the total number of injections is most important to me”
“Reducing out-of-pocket cost is most important to me”
“If A and B work equally well (i.e., same pregnancy rate) then I wouldn’t care”
”I would prefer B, but out-of-pocket cost would influence my choice”
Assuming there was no difference in your out-of-pocket cost for A and B, w
“I would definitely prefer treatment A”
“If both work equally well (i.e., same pregnancy rate) then Iwouldn’t care”
“I would definitely prefer treatment B”
“I don’t know”
If reducing the total number of injections is important to you (Treatment B),
to pay some extra for this, how much more would you be willing to pay?
“I would pay up to $100 more for treatment B”
“I would pay $100-500 more for treatment B”
Next, assume there is a difference in your ‘out-of-pocket’ cost for these two t
cost you about $260, while Treatment B will cost you about $650.What woul
“I would prefer Treatment A based on this difference”
“If both work equally well (i.e., same pregnancy rate) then I wouldn’t care”
“I would prefer Treatment B based on this difference”
Note: Treatment A=GnRH-agonist, Treatment B =GnRH-antagonist.
1Analysis of variance.tended not to know which treatment they would prefer
compared to older IVF patients (p=0.016). It could be
speculated that less experienced, younger IVF patients mightof respondent concerning treatment preferences,
Mean age (yrs) p1
ng fertility treatment?
33.5 0.66
33.5
33.2
34.6
hat would you prefer?
35 0.016
34.2
34.3
26.7
and you would be willing
33.5 0.025
35.7
reatments. Treatment A will
d you do based on this information?
33.5 0.176
35.1
36
Figure 2 Cost comparisons between GnRH-antagonist vs. GnRH-agonist. Cost-to-patient (in 2012 U.S. dollars) for GnRH-antagonist (back) [B]
and GnRH-agonist (front) [A] as measured in 11 retail pharmacies. Entries 1–3 were obtained from IVF specialty pharmacies, while data from sites
4–11 were derived from community pharmacies.
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GnRH-antagonist, yet this association was not supported by
our study data. Because questionnaire data were stratified
on the basis of IVF patients having previous or current ex-
perience working in a healthcare setting, we were able to
measure differences across groups depending on this param-
eter. In this investigation, 11.5% of patients reported a
health-related occupation where familiarity with injection
techniques and equipment would be different compared to
the general population. Indeed, evidence from this study
suggests that IVF patients who have a health occupation
background tend not to have a preference between GnRH-
agonist vs. GnRH-antagonist, if there is no difference in
treatment cost (p=0.036). Our data also revealed that pa-
tient education level influenced treatment preference in the
setting of no difference in cost, with more highly educated
IVF patients tending to prefer GnRH-antagonist (p=0.003).
Length of time trying to conceive (infertility duration) was
not associated with a preference for GnRH-antagonist in
this study of IVF patients (p>0.1).
Several limitations of this study should be acknowledged.
Patient income was not sampled by our questionnaire, so it
was impossible to stratify protocol preference by this
parameter. Also, patient opinion and actual clinical decisions
for IVF protocol may be quite different. Just because a pa-
tient may “dislike” a particular medication because it costs
too much does not necessarily mean that it will disappear
from her IVF calendar. In the context of an elective medical
service like IVF, the role of patient choice is not irrelevant,
however. It should be noted that the total expense of IVF
represents an aggregate of numerous cost centers, and the
contribution of either GnRH-a or GnRH-antagonist to over-
all expense might be nominal for some IVF patients. For
other patients, the total quantity of gonadotropins required
to complete IVF may be less when GnRH-antagonist is used[26], although precisely quantifying this effect was beyond
the scope of our investigation. The established practice of
pharmaceutical manufacturers giving away incentives such
as free samples, rebates, coupon offers etc. for various IVF
medications (including GnRH-antagonist) seems to recognize
the hardships encountered by IVF patients who are strug-
gling financially. Additionally, because our calculation of
non-reimbursed medication costs was based on data from
retail pharmacies serving patients in southern California,
generalizing our findings to other locations should be done
with caution. This investigation was not designed to follow
patients through their IVF cycles to verify which protocol
was actually used, or if their actual out-of-pocket cost
agreed with the pre-treatment estimate. However, because
our sample captured cost data from all establishments in
our immediate service area plus mail-order specialty phar-
macies, the ‘price to patient’ is considered accurate and the
difference between actual and predicted IVF patient costs
for this treatment component was probably marginal.
Conclusions
Lack of success and psychological stress are known to be
important background issues when IVF is discontinued,
and not surprisingly, these factors are very strongly asso-
ciated [27]. When personal economic resources are insuffi-
cient to fund further IVF treatment, this circumstance can
produce its own psychological stress. Because some practice
jurisdictions provide multiple cycles of IVF at zero cost to
the patient, research in these settings is especially inform-
ative because it removes the economic component from
the analysis of patient stress. For example, in the United
Kingdom where IVF may be subsidized, population-based
data revealed a relatively high attrition rate whereby IVF
patients on average tend to either succeed with a pregnancy
or drop-out from treatment altogether after only two
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versity of Oxford). Another IVF study in a Scandinavian
healthcare setting reported that among 450 couples not
achieving live birth, 208 completed their subsidized cycles,
but 242 discontinued IVF even though the patient would
have paid almost nothing (i.e., payment would have been
made by the state). Reasons for stopping treatment
included psychological stress (26%), poor prognosis (25%),
spontaneous pregnancy (19%), physical burden (6%), serious
disease (2%), and other reasons (7%) [28]. Of note, some
locations within USA do mandate insurance coverage for
IVF and when these patients were sampled similar attrition
trends have been observed [29]. We anticipate future inves-
tigation into the behavioral economics of IVF patient pre-
ferences and value-based incentives in elective fertility
treatments can clarify our initial findings.
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